Sun Pharma's US Innovative Drug Sales Overtake Generics

Sun Pharmaceutical Industries Ltd has in Q2 of 2026 financial year, to a large extent, sold innovative medicines in the US market than generics. The achievement was a result of a robust market demand for Ilumya (psoriasis treatment), Cequa (ophthalmic product), and Odomzo (skin cancer therapy).

The increase in the sales was in fact due to the launch in July of Leqselvi, a new drug for alopecia (hair loss) developed by Sun, after a settlement Incyte Corp. The market has welcomed the drug, which was obtained by Sun in the acquisition of Concert Pharma for $576 million.

“By Q3 and Q4, sales of innovative medicines will still be on the rise as we have the cancer immunotherapy Unloxcyt to be launched,” commented Richard Ascroft, CEO of Sun Pharma’s North American business.

Worldwide innovative medicine sales amounted to $333 million in Q2FY26, representing a 16.4% year-on-year growth, and making up 20.2% of the total consolidated revenue. The first half sales were $644 million, which marked a 16.6% annual increase.

Also Read: WHO and Bayer Extend Pact to Tackle Neglected Diseases

Sun Pharma posted consolidated revenue of ?14,405 crore, an 8.6% increase YoY, and a net profit of ?3,118 crore, growing by 2.6% YoY. EBITDA was up 14.9% to ?4,527 crore with a 31.3% margin, and the R&D spending was ?783 crore (5.4% of sales).

Going forward, Sun will keep expanding its R&D pipeline, according to the Executive Chairman Dilip Shanghvi, who additionally mentioned the company’s anticipation for the FDA approval of the updated labeling of Unloxcyt before the US launch in the second half of FY26.